Filters
In young adults who have never smoked combustible tobacco, daily use of nicotine vape appears to have a negative effect on vascular function and cardiorespiratory fitness, according to a cross-sectional study.
In patients with inflammatory arthritis, temporary interruption of biologic or Janus kinase inhibitor (JAKi) therapies during supplemental COVID-19 vaccination does not help improve humoral immunogenicity and even increases flare risk, as shown in the pragmatic COVER trial.
Three proton pump inhibitors (PPIs) demonstrate cardiovascular safety in patients with acute myocardial infarction (MI) receiving dual antiplatelet therapy (DAPT), according to a study. Moreover, use of lansoprazole contributes to a reduced risk of gastrointestinal bleeding.
Patients with prostate cancer who are undergoing treatment may develop urethral complications over time regardless of treatment modality, according to a study.
Hypospadias repair during childhood draws satisfaction from adolescent patients who had undergone such procedure, particularly for cosmetic, urinary, and sexual outcomes, according to a study.
In individuals who underwent a total hip replacement (THR) for a displaced femoral neck fracture, the risk of dislocation over the first year after surgery was lower among those who were treated with a dual-mobility THR (DM-THR) compared with those who received a standard THR, results from the Duality trial suggest.
Treatment with gildeuretinol acetate capsules helps slow the growth of retinal atrophic lesions in individuals with Stargardt disease, according to the phase II TEASE-1 trial.
Macrolide resistance mutations (MRMs) were detected in more than 40 percent of Mycoplasma (M.) genitalium infections among individuals aged 14-59 years in the US in 2017-2018, representing approximately 1.4 million macrolide-resistant infections.
In the treatment or non-cirrhotic patients with chronic hepatitis C virus (HCV) infection, an 8-week course of sofosbuvir–velpatasvir combination has similar efficacy to the standard 12-week course, according to the open-label RESOLVE trial.
A phase II trial has demonstrated the safety and tolerability of combination treatment with intravesical cabazitaxel, gemcitabine, and cisplatin in patients with nonmuscle-invasive bacillus Calmette-Guérin (BCG)‒unresponsive urothelial carcinoma of the bladder.
